ArticleFrontiers in medicine2026
Inflammation-tumor burden interaction score stratifies survival after irinotecan-eluting bead chemoembolization for colorectal liver metastases.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization with irinotecan-loaded drug-eluting beads is an established locoregional option for selected patients with colorectal liver metastases who are not candidates for resection or ablation, but survival outcomes remain heterogeneous and simple prognostic tools are lacking. Methods: In this retrospective single-center study, we analyzed 70 patients treated between 2015 and 2024 to investigate whether the interaction between systemic inflammation and liver tumor burden can stratify survival after this procedure. Dynamic inflammatory change was quantified using the difference in the C-reactive protein-to-albumin ratio (ΔCAR) between baseline and early post-treatment assessments, and liver tumor burden was categorized by the number of metastases (< 5 vs. ≥ 5). These components were integrated into a composite chemoembolization-tumor burden-inflammation balance score (CT-IBS), and its association with early radiologic response, progression-free survival, and overall survival was evaluated using Kaplan-Meier analysis, receiver operating characteristic curves, and multivariable Cox regression. Results: At a median follow-up of 20.3 months, median progression-free and overall survival were 9.1 and 18.9 months, respectively, and early radiologic response (complete or partial) was observed in 75.7% of patients. Higher ΔCAR and a greater number of liver metastases were independently associated with inferior overall survival. The CT-IBS stratified patients into three distinct prognostic groups (median overall survival 27.3 vs. 17.8 vs. 8.6 months; Conclusion: Integrating dynamic inflammatory changes with liver tumor burden yields a simple, reproducible classification that may support risk stratification, patient selection, and post-treatment surveillance after irinotecan-eluting bead chemoembolization for colorectal liver metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.